Trials / Unknown
UnknownNCT03904823
A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC
An Open, Single-arm, Multi-center, Phase 2 Clinical Trial of Famitinib Combined With Epidermal Growth Factor Receptor (EGFR) Inhibitor HS-10296 in Patients With Advanced EGFR-mutant Non-Small Cell Lung Cancer (NSCLC)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 58 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy, safety and tolerability of famitinib combined with HS-10296 in subjects with advanced EGFR-mutant NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | famitinib po | Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study. |
| DRUG | HS-10296 po | Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study. |
Timeline
- Start date
- 2019-04-25
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2019-04-05
- Last updated
- 2022-07-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03904823. Inclusion in this directory is not an endorsement.